Reaction
Glomerulonephritis Membranous reporting signals
As of the last recalculation, Glomerulonephritis Membranous appears in 1,158 FAERS reports alongside 18 co-occurring drug terms. The strongest observed disproportionality signal is AGALSIDASE BETA (PRR 25.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Agalsidase Beta | 13 | 25.6 | 25.6 |
| Busulfan | 21 | 24.4 | 24.4 |
| Indomethacin | 17 | 23.4 | 23.4 |
| Anti-Thymocyte Globulin (Rabbit) | 10 | 22.5 | 22.5 |
| Raltegravir | 18 | 19.9 | 19.9 |
| Abacavir Sulfate | 10 | 18.6 | 18.6 |
| Tacrolimus Ointment 0.1% | 114 | 18.1 | 18.2 |
| Tacrolimus Extended-Release Capsules | 114 | 18.1 | 18.1 |
| Tacrolimus | 129 | 16.5 | 16.5 |
| Linagliptin | 13 | 12.9 | 13.0 |
| Nevirapine | 6 | 12.0 | 12.0 |
| Nebivolol | 10 | 11.4 | 11.4 |
| Atazanavir | 9 | 11.3 | 11.3 |
| Fludarabine Phosphate | 24 | 11.2 | 11.2 |
| Tofacitinib Citrate | 6 | 8.3 | 8.3 |
| Gefitinib | 4 | 8.0 | 8.0 |
| Entecavir | 5 | 7.7 | 7.7 |
| Nivolumab | 29 | 5.5 | 5.5 |